These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8028659)

  • 21. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions.
    Pollock PM; Pearson JV; Hayward NK
    Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transformation of human glioma cell lines with the p16 gene inhibits cell proliferation.
    Hama S; Sadatomo T; Yoshioka H; Kurisu K; Tahara E; Naruse I; Heike Y; Saijo N
    Anticancer Res; 1997; 17(3C):1933-8. PubMed ID: 9216647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
    Flores JF; Walker GJ; Glendening JM; Haluska FG; Castresana JS; Rubio MP; Pastorfide GC; Boyer LA; Kao WH; Bulyk ML; Barnhill RL; Hayward NK; Housman DE; Fountain JW
    Cancer Res; 1996 Nov; 56(21):5023-32. PubMed ID: 8895759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
    Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
    Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
    Bahuau M; Vidaud D; Jenkins RB; Bièche I; Kimmel DW; Assouline B; Smith JS; Alderete B; Cayuela JM; Harpey JP; Caille B; Vidaud M
    Cancer Res; 1998 Jun; 58(11):2298-303. PubMed ID: 9622062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
    Fujishita T; Mizushima Y; Kashii T; Kobayashi M
    Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Alteration of p15 and p16 gene in gastric cancer].
    Fushida S; Yonemura Y; Kawamura T; Nojima N; Satoh T; Fujita H; Michiwa Y; Fujimura T; Nishimura G; Miwa K; Miyazaki I
    Gan To Kagaku Ryoho; 1997 Jul; 24 Suppl 2():279-84. PubMed ID: 9263516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas.
    Tenan M; Benedetti S; Finocchiaro G
    Biochem Biophys Res Commun; 1995 Dec; 217(1):195-202. PubMed ID: 8526910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequent deletion and 5' CpG island methylation of the p16 gene in primary malignant lymphoma of the brain.
    Zhang SJ; Endo S; Ichikawa T; Washiyama K; Kumanishi T
    Cancer Res; 1998 Mar; 58(6):1231-7. PubMed ID: 9515810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Loss of CDKN2 gene and amplification of cyclin D1 gene in human esophageal cancer].
    Zheng J; Hou P; Zhou C
    Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):408-11. PubMed ID: 9387288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tribulations of the p16/MTS1/CDKN2 tumor gene suppressor: a continuing saga].
    Larsen CJ
    Bull Cancer; 1997 Apr; 84(4):427-30. PubMed ID: 9238169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of CDK inhibitor genes in immortalized and carcinoma derived breast cell lines.
    Zhou JN; Linder S
    Anticancer Res; 1996; 16(4A):1931-5. PubMed ID: 8712723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
    Grimison B; Langan TA; Sclafani RA
    Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
    Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
    Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A challenge to p16 gene as a major tumor suppressor.
    Marx J
    Science; 1994 Jun; 264(5167):1846. PubMed ID: 8009205
    [No Abstract]   [Full Text] [Related]  

  • 36. New tumor suppressor may rival p53.
    Marx J
    Science; 1994 Apr; 264(5157):344-5. PubMed ID: 8153613
    [No Abstract]   [Full Text] [Related]  

  • 37. Tumor suppression. Lessons in p16 from phylum Falconium.
    Sheaff RJ; Roberts JM
    Curr Biol; 1995 Jan; 5(1):28-31. PubMed ID: 7697342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rates of p16 (MTS1) mutations in primary tumors with 9p loss.
    Cairns P; Mao L; Merlo A; Lee DJ; Schwab D; Eby Y; Tokino K; van der Riet P; Blaugrund JE; Sidransky D
    Science; 1994 Jul; 265(5170):415-7. PubMed ID: 8023167
    [No Abstract]   [Full Text] [Related]  

  • 39. Methylation and p16: suppressing the suppressor.
    Little M; Wainwright B
    Nat Med; 1995 Jul; 1(7):633-4. PubMed ID: 7585141
    [No Abstract]   [Full Text] [Related]  

  • 40. p16INK4A as a human tumor suppressor.
    Shapiro GI; Rollins BJ
    Biochim Biophys Acta; 1996 Mar; 1242(3):165-9. PubMed ID: 8603068
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.